Research Article
Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study
Figure 3
Subgroup analyses: The younger patients (≤60 years old), the male patients, and the patients with AFP more than 400ng/ml, tumor size more than 5cm, or type III/IV PVTT, the median OS of TACE + sorafenib group was longer than that of TACE alone.